New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
07:38 EDTMDT, BCRMedtronic data should lead to approval of drug-coated balloon, says Wells Fargo
Wells fargo believes that data from a trial of Medtronic's drug-coated balloon will lead to approval of the device in 1H15 and establish the company as the market leader in the space. After analyzing data, the firm thinks data on a competing device from C.R. Bard (BCR) could be significantly less positive than the data on Medtronic's product. As a result, the firm anticipates that Medtronic will have a marketing advantage over C.R. Bard. Wells keeps an Outperform rating on Medtronic.
News For MDT;BCR From The Last 14 Days
Check below for free stories on MDT;BCR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2014
08:16 EDTMDTDeutsche Bank analysts hold an analyst/industry conference call
Subscribe for More Information
July 18, 2014
12:51 EDTMDTKey GOP senator signals readiness for inversion deal, The Hill says
Subscribe for More Information
July 16, 2014
10:36 EDTMDTTreasury calls on Congress to halt inversion deals
Subscribe for More Information
07:59 EDTMDTTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:18 EDTMDTScoliosis Research Society to hold annual meeting
Subscribe for More Information
July 14, 2014
07:12 EDTMDTCovidien downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information
July 10, 2014
08:02 EDTMDTCryoLife appoints Pat Mackin as President and CEO effective September 2
Mackin is expected to be appointed to the company's board after his employment begins. Steven Anderson will continue to serve CryoLife (CRY) as its President and Chief Executive Officer until Mackin's employment begins and then continue as its Executive Chairman. Mackin joins CryoLife from Medtronic (MDT), where he most recently served as President of Cardiac Rhythm Disease Management.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use